Andrew Newland, chief executive of ANGLE PLC (LON:AGL, OTCQX:ANPCY), tells Proactive London's Andrew Scott its device for detecting the early signs of cancer has shown promise harvesting fetal cells.
Parsortix appeared to score well against existing methods of non-invasive prenatal testing (NIPT).
Specifically, it was able to harvest intact cells, which could then be assessed for abnormalities such Down’s Syndrome.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...
FOR OUR FULL DISCLAIMER CLICK HERE